Mycobutin (Rifabutin)

• Rifabutin is a rifamycin antibiotic used to treat infections caused by mycobacteria.
• Mycobacterium avium complex (MAC) infection: reduces bacterial burden and improves clinical symptoms.
• Pulmonary tuberculosis (as part of combination therapy): enhances bacterial clearance when used with other anti‑TB agents.
• Extrapulmonary tuberculosis (as part of combination therapy): contributes to treatment of disseminated or meningeal TB.

• Rifabutin binds to the β‑subunit of bacterial DNA‑dependent RNA polymerase, blocking the initiation of RNA synthesis. This inhibition suppresses transcription in mycobacterial cells, leading to a bacteriostatic effect that limits bacterial replication and facilitates clearance by the host immune system.

Rifabutin may cause a range of adverse reactions, from mild to severe. Monitoring patients for these events is essential during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Vomiting: occasional episodes, often transient.
• Abdominal pain: crampy discomfort in the upper abdomen.
• Rash: erythematous skin eruptions, usually self‑limiting.
• Neutropenia: mild reduction in white blood cells.
• Elevated liver enzymes: mild transaminase rise.

Serious or Rare Side Effects

• Hepatotoxicity: severe liver injury requiring discontinuation.
• Severe neutropenia or agranulocytosis: marked drop in neutrophils, increasing infection risk.
• Hypersensitivity reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Visual disturbances: blurred vision or uveitis.
• Hemolytic anemia: rare destruction of red blood cells.
• Peripheral neuropathy: tingling or numbness in extremities.

• Before initiating Rifabutin therapy, clinicians should evaluate patient history and monitor specific parameters.
• Assess liver function before initiating therapy: obtain baseline transaminases and monitor periodically.
• Monitor complete blood count: watch for neutropenia or agranulocytosis during treatment.
• Avoid use in patients with known hypersensitivity to rifamycins: discontinue if allergic reaction occurs.
• Use with caution in patients receiving antiretroviral therapy: potential pharmacokinetic interactions may require dose adjustment.
• Pregnancy and breastfeeding: risk unknown, weigh benefits against potential fetal or infant harm.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Rifabutin interacts with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Macrolide antibiotics (e.g., clarithromycin): increased rifabutin plasma concentrations.
• Protease inhibitors (e.g., ritonavir): may markedly raise rifabutin levels.
• Antiretroviral agents (e.g., efavirenz): can reduce rifabutin exposure, compromising efficacy.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): may elevate rifabutin concentrations, requiring dose adjustment.
• Warfarin: rifabutin can alter INR, necessitating more frequent coagulation monitoring.
• Oral contraceptives: rifabutin may reduce hormonal effectiveness; advise alternative contraception.